SCHEMBL7884356

SCHEMBL7884356

Cc1cccc2cc(C(=O)N(C)C(=N)N)[nH]c12

nearest known ligand 0.50

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
NSD2 O96028 3/20 0.50
HRH4 Q9H3N8 6/20 0.48
DAO P14920 1/20 0.48
DDO Q99489 1/20 0.48
SMYD3 Q9H7B4 2/20 0.47
SETD2 Q9BYW2 3/20 0.44
KDM4E B2RXH2 5/20 0.42
HSD17B10 Q99714 2/20 0.42
ALDH1A1 P00352 4/20 0.41
HPGD P15428 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
GLA P06280 1/20 0.40
TP53 P04637 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7873309 0.99 NSD2 (0.49) NSD2HRH4DAODDOSMYD3
SCHEMBL7881936 0.86 HRH4 (0.50) NSD2HRH4SMYD3HSD17B10ALDH1A1
SCHEMBL7873722 0.86 GRIN2D (0.39) NSD2HRH4DAODDOKDM4E
Hydrochloric Acid SCHEMBL7885038 0.85 HRH4 (0.49) NSD2HRH4SMYD3HSD17B10ALDH1A1
Hydrochloric Acid SCHEMBL7877769 0.85 GRIN2D (0.38) NSD2HRH4DAODDOKDM4E
SCHEMBL7877623 0.85 HRH4 (0.49) NSD2HRH4DAOHSD17B10ALDH1A1
Hydrochloric Acid SCHEMBL7878220 0.84 HRH4 (0.48) NSD2HRH4DAOHSD17B10ALDH1A1
SCHEMBL7873932 0.83 HRH4 (0.51) HRH4KDM4EALDH1A1HPGDGLA
Hydrochloric Acid SCHEMBL7881429 0.82 HRH4 (0.50) HRH4KDM4EALDH1A1HPGDGLA
SCHEMBL7879692 0.81 APEX1 (0.61) HRH4KDM4EHSD17B10HPGDNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6248772-B1 HYPOTENSIVE AGENTS; ANTIARRHYTHMIA AGENTS; ANTIDIABETIC AGENTS; ANTIPROLIFERATIVE AGENTS SUMITOMO PHARMACEUTICALS CO., LTD. (JP) 2001-06-19 US disclosed
US-6169107-B1 USEFUL FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY INCREASED SODIUM/PROTON (NA.SUP.+ /H.SUP.+) EXCHANGER ACTIVITY, FOR EXAMPLE, HYPERTENSION, ARRHYTHMIA, ANGINA PECTORIS, CARDIAC HYPERTROPHY, DIABETES MELLITUS SUMITOMO PHARMACEUTICAL CO., LTD. (JP) 2001-01-02 US disclosed
EP-0622356-B1 Indoloylguanidine derivatives as inhibitors of sodium-hydrogen exchange SUMITOMO PHARMA (JP) 1998-07-01 EP disclosed
EP-0708091-A2 Indoloylguanidine derivatives SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 1996-04-24 EP disclosed
EP-0622356-A1 Indoloylguanidine derivatives as inhibitors of sodium-hydrogen exchange SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 1994-11-02 EP disclosed